OncoMatch/Clinical Trials/NCT04186520
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Is NCT04186520 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including 8/12-Day Production of Car-T Cells and 8/12-Day Production of Cryopreserved Car-T Cells for non hodgkin lymphoma (nhl).
Treatment: 8/12-Day Production of Car-T Cells · 8/12-Day Production of Cryopreserved Car-T Cells · 12-Day Production of Car-T Cells — This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Prior therapy
Must have received: anti-CD20 antibody (rituximab)
Must have received Rituximab or another cluster of differentiation 20 (CD20) antibody
Must have received: cytotoxic chemotherapy
at minimum two different chemotherapy regimens appropriate for their disease
Cannot have received: allogeneic CAR T-cell therapy
Prior allogeneic CAR T-cell therapy
Lab requirements
Blood counts
ANC≥1000 with no G-CSF within 72 hours or pegylated G-CSF within 14 days. Platelets≥50,000 with no transfusion within 72 hours.
Kidney function
creatinine clearance >60 ml/min AND serum Cr≤1.5 mg/dL. No IV hydration within 24 hours of eligibility. No dialysis dependent renal failure within three months of planned CAR infusion.
Liver function
AST and ALT <5 x ULN; serum bilirubin and alkaline phosphatase <5 x ULN, or considered not clinically significant as per the clinical PIs discretion (e.g. Gilbert's or indirect hyperbilirubinemia) or felt to be due to underlying disease.
Cardiac function
NYHA class I or II AND LVEF ≥45% (by ECHO or MUGA); pulmonary function: room air oxygen saturation ≥92%
Adequate hepatic function, defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <5 x upper limit of normal (ULN); serum bilirubin and alkaline phosphatase <5 x ULN, or considered not clinically significant as per the clinical PIs discretion (e.g. Gilbert's or indirect hyperbilirubinemia) or felt to be due to underlying disease. ANC≥1000 with no G-CSF within 72 hours or pegylated G-CSF within 14 days. Platelets≥50,000 with no transfusion within 72 hours. Adequate renal function, defined as creatinine clearance >60 ml/min AND serum Cr≤1.5 mg/dL. Adequate cardiac function as indicated by New York Heart Association (NYHA) classification I or II AND left ventricular ejection fraction of ≥45% (by cardiac echocardiogram (ECHO) or multigated acquisition scan (MUGA)) and adequate pulmonary function as indicated by room air oxygen saturation of ≥92%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Medical College of Wisconsin and Froedtert Hospital · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify